SCHEMBL606641

SCHEMBL606641

CC(C)C[C@H](NC(=O)[C@H](CCCNC(=N)N[N+](=O)[O-])NC(=O)c1cccs1)B1O[C@@H]2C[C@@H]3C[C@@H](C3(C)C)[C@]2(C)O1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 1/20 0.55
PSEN2 P49810 1/20 0.55
APH1B Q8WW43 1/20 0.55
NCSTN Q92542 1/20 0.55
APH1A Q96BI3 1/20 0.55
PSENEN Q9NZ42 1/20 0.55
PSMB5 P28074 18/20 0.53
PSMB1 P20618 9/20 0.52
PSMB11 A5LHX3 8/20 0.52
PSMD11 O00231 8/20 0.52
PSMD12 O00232 8/20 0.52
PSMD14 O00487 8/20 0.52
PSMA7 O14818 8/20 0.52
PSMD3 O43242 8/20 0.52
PSMC3 P17980 8/20 0.52
PSMA1 P25786 8/20 0.52
PSMA2 P25787 8/20 0.52
PSMA3 P25788 8/20 0.52
PSMA4 P25789 8/20 0.52
PSMB8 P28062 8/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15628821 0.92 PSEN1 (0.59) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL606334 0.92 PSMB5 (0.52) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL607054 0.91 PSEN1 (0.53) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL606898 0.90 PSEN1 (0.68) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL607615 0.90 PSMB5 (0.53) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL608333 0.89 PSMB5 (0.53) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL1480133 0.89 PSEN1 (0.55) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL606026 0.89 PSEN1 (0.58) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL605898 0.89 PSMB5 (0.52) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL608735 0.88 PSMB5 (0.58) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1660507-B2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME MILLENNIUM PHARM INC (US) 2017-01-04 EP claimed
EP-1660507-B9 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-03-24 EP claimed
EP-1660507-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2009-08-05 EP claimed
US-8546608-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2013-10-01 US disclosed
US-20120041196-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2012-02-16 US disclosed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 US disclosed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 US disclosed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 US disclosed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 US disclosed
US-7576206-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME PSMB11, PSMB5, PSMB6 PSEN1 697/4885PSEN2 1334/4885APH1B 727/4885
US-20120041196-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 PSEN1 697/4885PSEN2 1334/4885APH1B 727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.